恶性肿瘤相关性心房颤动的研究现状

陈雨卉; 王运松; 夏云龙

doi:10.13201/j.issn.1001-1439.2021.02.018

恶性肿瘤相关性心房颤动的研究现状

- 大连医科大学附属第一医院心内科(辽宁大连, 116011)

详细信息

通讯作者: 夏云龙,E-mail:yunlong_xia@126.com

中图分类号: R730；R541.75

收稿日期: 2020-08-27

Research progress of malignant tumor-associated atrial fibrillation

- Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, China

More Information

Corresponding author: XIA Yunlong, E-mail: yunlong_xia@126.com

Received Date: 27 August 2020

摘要

摘要: 流行病学研究表明,恶性肿瘤患者发生心房颤动(房颤)的风险高于一般人群。相对于传统房颤的发病机制,合并恶性肿瘤的房颤存在一些与肿瘤环境及治疗相关的特殊机制。由于恶性肿瘤合并房颤患者的出血与栓塞风险难以平衡,如何处理合并恶性肿瘤的房颤已成为当前肿瘤心脏病学中的热点问题。本文主要就恶性肿瘤相关性房颤的流行病学、发病机制以及治疗等方面进行归纳探讨。
- 恶性肿瘤 /
- 心房颤动 /
- 流行病学
Abstract: Many epidemiological studies have shown that the risk of atrial fibrillation(AF) in patients with malignant tumor is higher than that in the general population. Compared with the traditional pathogenesis of AF, AF with malignant tumor has some special mechanisms related to tumor environment and treatment. Because malignant tumor will increase the risk of thromboembolism and bleeding, it is difficult to balance the risk of embolism and bleeding in such patients. How to deal with AF patients with malignant tumor has become a hot issue in Oncocardiology. This article mainly discusses the epidemiology, pathogenesis and treatment of malignant tumor associated AF.
- neoplasms /
- atrial fibrillation /
- epidemiology

HTML全文

参考文献(36)

[1]	Abdel-Qadir H,Thavendiranathan P,Fung K,et al.Association of early-stage breast cancer and subsequent chemotherapy with risk of atrial fibrillation[J].JAMA Netw Open,2019,2(9):e1911838.
[2]	Kattelus H,Kesaniemi YA,Huikuri H,et al.Cancer increases the risk of atrial fibrillation during long-term follow-up(OPERA study)[J].PLoS One,2018,13(10):e0205454.
[3]	Herrmann J.Adverse cardiac effects of cancer therapies:cardiotoxicity and arrhythmia[J].Nat Rev Cardiol,2020,17(8):474-502.
[4]	Yuan M,Zhang Z,Tse G,et al.Association of cancer and the risk of developing atrial fibrillation:a systematic review and meta-analysis[J].Cardiol Res Pract,2019,2019:8985273.
[5]	Saliba W,Rennert HS,Gronich N,et al.Association of atrial fibrillation and cancer:Analysis from two large population-based case-control studies[J].PLoS One,2018,13(1):e0190324.
[6]	Conen D,Wong JA,Sandhu RK,et al.Risk of malignant cancer among women with new-onset atrial fibrillation[J].JAMA Cardiol,2016,1(4):389-396.
[7]	Hung YP,Hu YW,Liu CJ,et al.Risk and predictors of subsequent cancers of patients with newly-diagnosed atrial fibrillation-A nationwide population-based study[J].Int J Cardiol,2019,296:81-86.
[8]	Cuenca JA,Laserna A,Martin P,et al.Higher mortality in new-onset atrial fibrillation in cancer patients with septic shock[J].Critl Care Med,2020,48:122.
[9]	Farmakis D,Papingiotis G,Filippatos G,et al.Atrial fibrillation in cancer[J].Cardiovasc Complic in Cancer Therapy,2019,5(5):113-121.
[10]	Chu G,Versteeg HH,Verschoor AJ,et al.Atrial fibrillation and cancer-An unexplored field in cardiovascular oncology[J].Blood Rev,2019,35:59-67.
[11]	Qian S,Golubnitschaja O,Zhan X.Chronic inflammation:key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles[J].EPMA J,2019,10(4):365-381.
[12]	胡润晖,胡建平,洪葵.自主神经与心房颤动的研究进展[J].临床心血管病杂志,2020,36(1):86-89.
[13]	Wijesurendra RS,Casadei B.Mechanisms of atrial fibrillation[J].Heart,2019,105(24):1860-1867.
[14]	刘彤,夏云龙.抗肿瘤治疗与心房颤动[J].实用心电学杂志,2019,28(6):397-401,428.
[15]	吕海辰,夏云龙.发展中的肿瘤心脏病学[J].中国医刊,2019,54(8):816-819.
[16]	Rhea IB,Lyon AR,Fradley MG.Anticoagulation of cardiovascular conditions in the cancer patient:review of old and new therapies[J].Curr Oncol Rep,2019,21(5):45.
[17]	Akazawa H.Onco-cardiology in the field of hematology[J].Rinsho Ketsueki,2019,60(9):1372-1377.
[18]	Virani SS,Alonso A,Benjamin EJ,et al.Heart disease and stroke statistics-2020 update:a report from the American Heart Association[J].Circulation,2020,141(9):e139-e596.
[19]	Ramos J,álvarez-Bustos A,Soriano M,et al.Ideal cardiovascular health(ICVH)in patients with a recent diagnosis of colorectal cancer(CRC)[J].Ann Oncol,2017,28(5):v563.
[20]	Sanz AP,Gómez J.AF in cancer patients:a different need for anticoagulation?[J].Eur Cardiol,2019,14(1):65-67.
[21]	Hu WS,Lin CL.Comparison of CHA2DS2-VASc,CHADS2 and HATCH scores for the prediction of new-onset atrial fibrillation in cancer patients:A nationwide cohort study of 760,339 study participants with competing risk analysis[J].Atherosclerosis,2017,266:205-211.
[22]	Pamela J B,Joseph H,Matthew K,et al.Warfarin use and mortality,stroke,and bleeding outcomes in a cohort of elderly patients with non-valvular atrial fibrillation[J].J Atr Fibrillation,2019,12(1):2155.
[23]	Lee YJ,Park JK,Uhm JS,et al.Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy[J].Int J Cardiol,2016,203:372-378.
[24]	Casula M,Fortuni F,Fabris F,et al.Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation:a meta-analysis[J].J Cardiovasc Med(Hagerstown),2020,21(8):570-576.
[25]	Acanfora D,Ciccone MM,Scicchitano P,et al.Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and high thromboembolic risk.a systematic review[J].Front Pharmacol,2019,10:1048.
[26]	Kim K,Lee YJ,Kim TH,et al.Effect of non-vitamin k antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer[J].Korean Circ J,2018,48(5):406-417.
[27]	马长生.2019年心房颤动治疗新进展[J].临床心血管病杂志,2019,35(11):967-971.
[28]	Pardo Sanz A,Rincón LM,Guedes Ramallo P,et al.Current status of anticoagulation in patients with breast cancer and atrial fibrillation[J].Breast,2019,46:163-169.
[29]	王晨曦,杨萍萍,李忠城,等.在癌症和非癌症患者中非维生素K拮抗剂口服抗凝药的相对效益分析:随机对照试验的Meta分析[J].临床心血管病杂志,2020,36(1):65-69.
[30]	Fitzgerald JL,Howes LG.Drug interactions of direct-acting oral anticoagulants[J].Drug Saf,2016,39(9):841-845.
[31]	Malavasi VL,Fantecchi E,Gianolio L,et al.Atrial fibrillation in patients with active malignancy and use of anticoagulants:Under-prescription but no adverse impact on all-cause mortality[J].Eur J Intern Med,2019,59:27-33.
[32]	Stepien K,Nowak K,Zalewski J,et al.Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism.A pilot study[J].Vascul Pharmacol,2019,120:106567.
[33]	Correction in the Article by Kirchhof et al.2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Rev Esp Cardiol(Engl Ed),2017,70(11):1031.
[34]	Chandrasekhar S,Fradley MG.QT interval prolongation associated with cytotoxic and targeted cancer therapeutics[J].Curr Treat Options Oncol,2019,20(7):55.
[35]	Goehring EL Jr,Bohn RL,Pezzullo J,et al.Outcomes associated with dronedarone use in patients with atrial fibrillation[J].Am J Cardiol,2020,135:77-83.
[36]	Giustozzi M,Ali H,Reboldi G,et al.Safety of catheter ablation of atrial fibrillation in cancer survivors[J].J Interven Cardiac Electrophysiol,2020,DOI:10.1007/s10840-020-00745-7.